Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:37:10.668Z.
Calculation as of: 2026-10-06T17:37:10.668Z.
Quote observation: 2026-10-06T17:30:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2baa5019f568993ecceb1943c30cf17443c8d153a00c2cc4d930c3e59df60e4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.10M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.18M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.02M
Price/OCF Ratio
N/A
TTM Avg
11.16
3Y Avg
11.16
5Y Avg
11.16
Market Cap
$5.20M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.34M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.10M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A | 15.43 | 17.34 | 17.34 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.18M | N/A | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.02M | N/A | 11.16 | 11.16 | 11.16 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.34M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.28M | N/A | 6.25 | 6.24 | 6.24 |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.35M | N/A | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.31M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
